SHANGHAI, China and REDWOOD CITY, Calif., November 15, 2021 — Shanghai Junshi Biosciences Co., Ltd. (鈥淛unshi Biosciences鈥? HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (鈥淐oherus鈥? Nasdaq: CHRS) announced today that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient population less than 200,000 in the U.S. The designation provides incentives to advance development and commercialization of rare disease drugs.